Tau imaging with [18F]THK‐5351 in progressive supranuclear palsy
Abstract
Background and purpose: Visualization of pathogenic protein aggregates is crucial to elucidate pathomechanisms and to make an accurate diagnosis in many neurodegenerative conditions. Aggregates of the microtubule‐binding protein, tau, are one of the most important pathogenic molecules in neurodegenerative disorders. Progressive supranuclear palsy (PSP) is characterized by the deposition of tau proteins in some specific area such as the basal ganglia and brainstem. We tried to detect tau lesions in the brains of living patients with PSP with a novel positron emission tomography (PET) tracer, [18 F]THK‐5351, which we have recently developed. Methods: Paraffin‐embedded brain sections of the patients with PSP were used for autoradiography with [3 H]THK‐5351 and immunohistochemistry. Nine healthy controls, 13 patients with Alzheimer's disease and three patients with PSP participated in this PET study with [18 F]THK‐5351. To detect amyloid‐β deposition, PET imaging with Pittsburgh compound B was also performed. Results: Autoradiography in the brain sections of patients with PSP demonstrated [3 H]THK‐5351 binding to tau deposits with a high selectivity. Although patients with PSP exhibited no remarkable [18 F]THK‐5351 retention in the temporal cortex, significantly higher tracer retention was observed in the globus pallidus and midbrain. In contrast, amyloid imaging with Pittsburgh compound B showed no remarkable accumulation in the cerebral cortex of PSP. Conclusions: We conclude that [18 F]THK‐5351 PET can potentially be used to detect the regional brain distribution of tau lesions in PSP, thereby facilitating the differential diagnosis of neurodegenerative disorders associated with tau protein.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Earlier PET investigations have detected alterations in PSP with ligands for tau and for microglial activation.
“Previous positron emission tomography (PET) has indicated changes in PSP using ligands targeting tau8–16 and microglial activation17,18.”
From Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy (2020) · cites this paper as [12]
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · see citing works
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · see citing works
Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538 · see citing works
Tau positron emission tomographic imaging in aging and early <scp>A</scp> lzheimer disease
Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986 · see citing works
Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., Zhang, M.-R., Trojanowski, J. Q., Lee, V. M.-Y., Ono, M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.037 · Cited by 760 · see citing works
Self-citationEarly clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807
Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M.-Y., Shankle, W. R., Elizarov, A., & Kolb, H. C. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122059 · Cited by 651 · see citing works
A clinical rating scale for progressive supranuclear palsy
Golbe, L. I., & Ohman‐Strickland, P. (2007) · Brain · doi:10.1093/brain/awm032 · Cited by 614 · see citing works
Tau imaging: early progress and future directions
Villemagne, V. L., Fodero-Tavoletti, M. T., Masters, C. L., & Rowe, C. C. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70252-2 · Cited by 501 · see citing works
Self-citationWilliams, D. R., Holton, J. L., Strand, C., Pittman, A. M., de Silva, R., Lees, A. J., & Révész, T. (2007) · Brain · doi:10.1093/brain/awm104 · Cited by 415 · see citing works
Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Tago, T., Hiraoka, K., Watanuki, S., Shidahara, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.164848 · Cited by 330 · see citing works
Self-citationNon-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET
Okamura, N., Furumoto, S., Fodero‐Tavoletti, M. T., Mulligan, R. S., Harada, R., Yates, P. A., Pejoska, S., Kudo, Y., Masters, C. L., Yanai, K., et al. (2014) · Brain · doi:10.1093/brain/awu064 · Cited by 266 · see citing works
Self-citationWilliams, D. R. (2006) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2006.01153.x · Cited by 259 · see citing works
de Silva, R., Lashley, T., Gibb, G., Hanger, D. P., Hope, A., Reid, A. R., Bandopadhyay, R., Utton, M. A., Strand, C., Jowett, T. P., et al. (2003) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2003.00463.x · Cited by 220 · see citing works
Current and novel therapeutic molecules and targets in Alzheimer's disease
Kumar, A., Nisha, C. M., Silakari, C., Sharma, I., Anusha, K., Gupta, N., Nair, P., Tripathi, T., & Kumar, A. (2015) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2015.04.001 · Cited by 153 · see citing works
[18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease
Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Hiraoka, K., Watanuki, S., Shidahara, M., Miyake, M., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3035-4 · Cited by 128 · see citing works
Self-citationPET Imaging of Tau Pathology in Alzheimer’s Disease and Tauopathies
James, O. G., Doraiswamy, P. M., & Borges-Neto, S. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00038 · Cited by 104 · see citing works
In vivo tau imaging: Obstacles and progress
Villemagne, V. L., & Okamura, N. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.04.013 · Cited by 96 · see citing works
Self-citationIkeda, K., Akiyama, H., Kondo, H., & Haga, C. (1995) · Acta Neuropathologica · doi:10.1007/bf00307644 · Cited by 80 · see citing works
Ishiki, A., Okamura, N., Furukawa, K., Furumoto, S., Harada, R., Tomita, N., Hiraoka, K., Watanuki, S., Ishikawa, Y., Tago, T., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140311 · Cited by 77 · see citing works
Self-citationNeuroimaging biomarkers in Alzheimer’s disease and other dementias
Villemagne, V. L., & Chételat, G. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.004 · Cited by 48 · see citing works
Self-citationAdvances in CNS Imaging Agents: Focus on PET and SPECT Tracers in Experimental and Clinical Use
George, N., Gean, E. G., Nandi, A., Фролов, Б. А., Zaidi, E., Lee, H., Brašić, J. R., & Wong, D. F. (2015) · CNS Drugs · doi:10.1007/s40263-015-0237-z · Cited by 20 · see citing works
O4‐03‐01: MICROGLIAL EXPRESSION OF ALZHEIMER'S DISEASE ASSOCIATED RISK GENES
Kofler, J., Wang, X., Kamboh, M. I., Sweet, R. A., López, O. L., & MURDOCH, G. H. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.04.396 · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Imaging and fluid biomarkers in frontotemporal dementia
Meeter, L. H., Kaat, L. D., Rohrer, J. D., & van Swieten, J. C. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.75 · Cited by 210 · see citing works
Schonhaut, D. R., McMillan, C. T., Spina, S., Dickerson, B. C., Siderowf, A., Devous, M. D., Tsai, R., Winer, J., Russell, D. S., Litvan, I., et al. (2017) · Annals of Neurology · doi:10.1002/ana.25060 · Cited by 175 · see citing works
Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy
Malpetti, M., Passamonti, L., Rittman, T., Jones, P. S., Vázquez Rodríguez, P., Bevan‐Jones, W. R., Hong, Y. T., Fryer, T. D., Aigbirhio, F. I., O'Brien, J. T., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25911 · Cited by 83 · see citing works
[18F]‐THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy
Brendel, M., Schönecker, S., Höglinger, G., Lindner, S., Havla, J., Blautzik, J., Sauerbeck, J., Rohrer, G., Zach, C., Vettermann, F., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00440 · Cited by 72 · see citing works
Self-citation
- Authors
- Ishiki, A., Harada, R., Okamura, N., Tomita, N., Rowe, C. C., Villemagne, V. L., Yanai, K., Kudo, Y., Arai, H., Furumoto, S., Tashiro, M., & Furukawa, K.
- Affiliations
- Tohoku University (JP)
- Austin Hospital (AU)
- The University of Melbourne (AU)
- Corresponding author
- Furukawa, K.
- ORCID
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2016-10-31
- Volume
- 24
- Issue
- 1
- Pages
- 130-136
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W2545175005
- Cited by
- 92
- References
- 23
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 1 · 2023: 6 · 2022: 10 · 2021: 9 · 2020: 6 · 2019: 9 · 2018: 24 · 2017: 21
- FWCI
- 14.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Funders
- GE Healthcare
- Center for Scientific Review
- New Energy and Industrial Technology Development Organization (09E51025a)
- Ministry of Health, Labour and Welfare
- Ministry of Education, Culture, Sports, Science, and Technology
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- progressive supranuclear palsy, tau imaging, PET radiotracer, globus pallidus, midbrain, amyloid-beta, Pittsburgh compound B, autoradiography
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Aniline Compounds, Brain, Female, Humans, Male, Supranuclear Palsy, Progressive, Thiazoles, tau Proteins, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
